Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Radke

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Gynecologic Oncology|December 30, 2020
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutationsTalayeh S Ghezelayagh, Kathryn P Pennington, Barbara M Norquist, et al.
Science Translational Medicine|July 20, 2022
Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomasFrancesca Menghi, Kalyan Banda, Pooja Kumar, et al.
Oncogene|June 25, 2024
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutationsTalayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
Nature Communications|December 13, 2019
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistanceYifan Wang, Andrea J Bernhardy, Joseph Nacson, et al.
Gynecologic Oncology|December 17, 2019
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinomaJeffrey D Krimmel-Morrison, Talayeh S Ghezelayagh, Shenyi Lian, et al.
Plos One|May 21, 2014
Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureusAlan J Weaver, Joyce B Shepard, Royce A Wilkinson, et al.
Gynecologic Oncology|August 11, 2024
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutationsXin Ray Tee, Emma Hazard, Elena Latorre-Esteves, et al.
Clinical Research in Cardiology Supplements|February 18, 2016
[Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)]Detlev Willemsen, C Cordes, B Bjarnason-Wehrens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Gynecologic Oncology|December 30, 2020
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutationsTalayeh S Ghezelayagh, Kathryn P Pennington, Barbara M Norquist, et al.
Science Translational Medicine|July 20, 2022
Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomasFrancesca Menghi, Kalyan Banda, Pooja Kumar, et al.
Oncogene|June 25, 2024
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutationsTalayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
Nature Communications|December 13, 2019
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistanceYifan Wang, Andrea J Bernhardy, Joseph Nacson, et al.
Gynecologic Oncology|December 17, 2019
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinomaJeffrey D Krimmel-Morrison, Talayeh S Ghezelayagh, Shenyi Lian, et al.
Plos One|May 21, 2014
Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureusAlan J Weaver, Joyce B Shepard, Royce A Wilkinson, et al.
Gynecologic Oncology|August 11, 2024
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutationsXin Ray Tee, Emma Hazard, Elena Latorre-Esteves, et al.
Clinical Research in Cardiology Supplements|February 18, 2016
[Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)]Detlev Willemsen, C Cordes, B Bjarnason-Wehrens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Pageof 10